This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…
Without a strong biosimilars market, costs for biologics in the US continue trending upward. The world of drug patents for biosimilars in the United States is far more complex than…
The post Understanding the Barriers to US Biosimilars appeared …
Formularies come into effect at the hospital level and the individual insurer level When developed and managed with due care and consideration, drug formularies can be a good tool for…
The post Formulary Decisions: Exploring the Ethics of Drug Ap…
Although currently tiny and narrowly focused on a handful of disease areas and countries, the biosimilar industry is set to expand as patents expire on top biologics, payers push for…
The post Top 5 Challenges Faced By Biosimilars appeared first …
For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, we knew…
The post Top 6 issues facing the biotechnology industry appea…
This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…
By: Pankaj Mondal, DrugPatentWatch Staff Writer When it comes to measuring the success of a new drug, the amount of time required to complete the entire approval process become a…
The post Accelerating Drug Approvals in the US appeared first on D…
The US pharmaceutical industry is heavily competitive, with nine out of the top ten pharmaceutical companies based in the US. In recent years though, the market has become even more competitive…
The post The Importance of Pharmaceutical Competito…
This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
The post C…
Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector,…
The post Making Medicines Affordable…